Ovarian cancer has the highest incidence in peri-and postmenopausal, and due to its late diagnosis and poor prognosis, it is the fourth leading cause of cancer death worldwide, alongside breast, colorectal, lung and cervix cancers. Ovarian cancer initially responds to conventional chemotherapy, slowing the growth of the tumor mass, however in an unexpected way, many women can develop chemo resistance to specific treatment. Given that P-MAPA possesses immunomodulatory and oncostatic activities and also seems to potentiate the effects of some chemotherapeutic agents, such as cisplatin, this study aims to evaluate the effect of ovarian tumor induction and the influence of P-MAPA, combined or not to cisplatin on the TLR2 and TLR4 signaling pathway in Fischer 344 rats. For this purpose, the following parameters will be investigated: estrous cycle monitoring, evaluation of the frequency and characterization of different types of ovarian tumors through histopathology, immunoreactivity and quantification of TLR2, TLR4, MyD88, NF-kB, and IRF3 using immunohistochemical and Western blot analysis. These results will assist in clarifying the effects of P-MAPA combined or not to cisplatin on the inflammation process mediated by TLRs of tumor cells associated with serous ovarian cancer.
News published in Agência FAPESP Newsletter about the scholarship: